70 Participants Needed

GSBR-1290 for Obesity

Recruiting at 2 trial locations
CO
Overseen ByClinical Operations Lead
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Gasherbrum Bio, Inc
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new medication called GSBR-1290 in tablet and capsule forms on healthy overweight/obese individuals. It aims to see how the body processes the drug and compares the effectiveness of different forms.

Do I have to stop taking my current medications for the GSBR-1290 trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Are You a Good Fit for This Trial?

This clinical trial is for healthy adult men and women who are overweight or obese, aged between 18 to 75 years old with a BMI of at least 27.0 kg/m^2. Participants must understand the study procedures and agree to follow them by signing an informed consent form.

Inclusion Criteria

Body mass index (BMI) greater than or equal to 27.0 kilogram per square meter (kg/m^2).
Provided evidence of a signed informed consent before any study-related activities are initiated and be willing to comply with all study procedures.
I am an adult who is overweight or obese but otherwise healthy.

Exclusion Criteria

I have a significant health condition affecting my heart, lungs, liver, kidneys, blood, stomach, hormones, immune system, skin, or nerves.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Part 1

Participants receive a single dose of GSBR-1290 oral capsule or tablet in a crossover design

2 weeks
2 visits (in-person)

Treatment Part 2

Participants receive GSBR-1290 or placebo tablets once daily for 12 weeks, with further randomization in the last 4 weeks

12 weeks
Weekly visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • GSBR-1290
Trial Overview The trial is testing GSBR-1290, a new medication in capsule/tablet form, against a placebo (a pill with no active drug) to assess its safety and how it's processed by the body when given repeatedly to healthy overweight/obese individuals.
How Is the Trial Designed?
5Treatment groups
Experimental Treatment
Group I: Part 2 (Cohort 3): GSBR-1290/Placebo Tablet and GSBR-1290/Placebo CapsuleExperimental Treatment2 Interventions
Group II: Part 2 (Cohort 2): GSBR-1290/Placebo TabletExperimental Treatment2 Interventions
Group III: Part 2 (Cohort 1): GSBR-1290/Placebo TabletExperimental Treatment2 Interventions
Group IV: Part 1(Sequence 2: Tablet to Capsule): GSBR-1290 Tablet/GSBR-1290 CapsuleExperimental Treatment1 Intervention
Group V: Part 1 (Sequence 1: Capsule to Tablet): GSBR-1290 Capsule/GSBR-1290 TabletExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Gasherbrum Bio, Inc

Lead Sponsor

Trials
3
Recruited
230+

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Lead Sponsor

Trials
5
Recruited
530+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security